NEW YORK, July 27 /PRNewswire-FirstCall/ - Genesis Bioventures, Inc. (GBI) today announced that its President and CEO, Douglas C. Lane, will present the restructured Genesis Bioventures at the Financial Services Exchange, Inc. (FSX) 92nd consecutive Connect for Success Conference, July 27-29, 2006 at the Omni Royal Orleans Hotel in New Orleans, LA.
“I am very pleased to have this opportunity to be able to present the newly structured Genesis Bioventures, Inc. at the Connect for Success Conference in New Orleans,” said Mr. Lane. “The FSX conference is an excellent forum for us to begin introducing our restructured company to the investment community and to discuss our commercialization plans.”
Mr. Lane joined the Company as CEO and President in April 2006 to implement the reorganization and restructuring plan of the Company. The plan has many facets and includes commercial development of its diagnostic test for breast cancer risk, the Mammastatin Serum Assay, as well as commercialization through exclusive worldwide sales, marketing and distribution agreements for a rapid assay to detect mad cow disease.
FSX conferences typically provide “a nationwide network of broker/dealers who serve as a captive audience for a combination of public companies looking for exposure, direct investment opportunities, private placements, REITS, and 1031 exchange programs. Connect for Success investment conferences are all about building relationships and discovering new investment opportunities.”
About Genesis Bioventures, Inc.
Genesis Bioventures, Inc. is a biomedical development corporation focusing on the development and marketing of novel diagnostics and therapeutics in oncology and neurodegenerative diseases.
This press release may contain statements that constitute “forward-looking statements” as defined under U.S. federal securities laws. Generally, the words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “establish,” “project” and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from Genesis’ historical experience and its present expectations or projections. These risks include, but are not limited to: actual use of the Rapid Prion Detection assays in slaughterhouses; actual commercialization of assays for transmissible spongiform encephalopathies in animals and humans; GBI’s ability to transition its corporate restructuring; to generate revenues and net income; ability to obtain personnel and directors familiar with investment, biotechnology, and pharmaceutical industries; commercialization of products through Prion Developmental Laboratories; our ability to become an industry leader; changes in economic conditions; the competitive environment within the biomedical industry; GBI’s ability to capture market share; the effectiveness of GBI’s advertising and marketing programs; ability to raise additional capital; ability to achieve earnings goals; regulatory and legal changes; ability to penetrate developing and emerging markets; litigation uncertainties; and other risks discussed in GBI’s filings with the SEC, including the Annual Report on Form 10-KSB, Quarterly Reports on Form 10-QSB, and Current Reports on Form 8-K, which reports are available from the SEC. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise any forward-looking statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
CONTACT: GBI Investor Relations: (604) 542-0820, gbi@gnsbio.com, www.gnsbio.com; Aurelius Consulting Group: (800) 644-6297, info@aurcg.com, www.runonideas.com
Genesis Bioventures, Inc.
CONTACT: GBI Investor Relations: (604) 542-0820, gbi@gnsbio.com,www.gnsbio.com; Aurelius Consulting Group: (800) 644-6297, info@aurcg.com,www.runonideas.com
